APA (7th ed.) Citation

Mendell, J., Muntoni, F., McDonald, C., Mercuri, E., Ciafaloni, E., Komaki, H., . . . Singh, T. (2024). D.4 Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy (EMBARK): Pivotal Phase 3 primary results. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 51, S9. https://doi.org/10.1017/cjn.2024.95

Chicago Style (17th ed.) Citation

Mendell, JR, et al. "D.4 Safety and Efficacy of Delandistrogene Moxeparvovec Versus Placebo in Duchenne Muscular Dystrophy (EMBARK): Pivotal Phase 3 Primary Results." The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques 51 (2024): S9. https://doi.org/10.1017/cjn.2024.95.

MLA (9th ed.) Citation

Mendell, JR, et al. "D.4 Safety and Efficacy of Delandistrogene Moxeparvovec Versus Placebo in Duchenne Muscular Dystrophy (EMBARK): Pivotal Phase 3 Primary Results." The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques, vol. 51, 2024, p. S9, https://doi.org/10.1017/cjn.2024.95.